Literature DB >> 32086769

We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can.

Elliot B Tapper1,2, Jagpreet Chhatwal3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32086769      PMCID： PMC7156303          DOI： 10.1007/s40273-020-00892-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  10 in total

1.  Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.

Authors:  Mohammad Nasser Kabbany; Praveen Kumar Conjeevaram Selvakumar; Kymberly Watt; Rocio Lopez; Zade Akras; Nizar Zein; William Carey; Naim Alkhouri
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

2.  Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study.

Authors:  Alina M Allen; Terry M Therneau; Joseph J Larson; Alexandra Coward; Virend K Somers; Patrick S Kamath
Journal:  Hepatology       Date:  2018-03-23       Impact factor: 17.425

Review 3.  Pharmacotherapy for NASH: Current and emerging.

Authors:  Monica A Konerman; Jacob C Jones; Stephen A Harrison
Journal:  J Hepatol       Date:  2017-11-06       Impact factor: 25.083

Review 4.  Use of Liver Imaging and Biopsy in Clinical Practice.

Authors:  Elliot B Tapper; Anna S-F Lok
Journal:  N Engl J Med       Date:  2017-08-24       Impact factor: 91.245

5.  Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States.

Authors:  Neehar D Parikh; Wesley J Marrero; Jingyuan Wang; Justin Steuer; Elliot B Tapper; Monica Konerman; Amit G Singal; David W Hutton; Eunshin Byon; Mariel S Lavieri
Journal:  Hepatology       Date:  2018-05-14       Impact factor: 17.425

6.  Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.

Authors:  Pierre Johansen; Daniel Howard; Ryan Bishop; Søren Ilsøe Moreno; Kristine Buchholtz
Journal:  Pharmacoeconomics       Date:  2020-05       Impact factor: 4.981

7.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Authors:  Arun J Sanyal; Stephen A Harrison; Vlad Ratziu; Manal F Abdelmalek; Anna Mae Diehl; Stephen Caldwell; Mitchell L Shiffman; Raul Aguilar Schall; Catherine Jia; Bryan McColgan; C Stephen Djedjos; John G McHutchison; G Mani Subramanian; Robert P Myers; Zobair Younossi; Andrew J Muir; Nezam H Afdhal; Jaime Bosch; Zachary Goodman
Journal:  Hepatology       Date:  2019-05-28       Impact factor: 17.425

8.  Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.

Authors:  Alina M Allen; Holly K Van Houten; Lindsey R Sangaralingham; Jayant A Talwalkar; Rozalina G McCoy
Journal:  Hepatology       Date:  2018-09-20       Impact factor: 17.425

Review 9.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

10.  The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study.

Authors:  Maria-Magdalena Balp; Nancy Krieger; Raymond Przybysz; Nate Way; Jennifer Cai; Dion Zappe; Sarah Jane McKenna; Garth Wall; Nico Janssens; Elliot Tapper
Journal:  JHEP Rep       Date:  2019-06-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.